Helping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher's ecosystem of industry-leading technologies

通过整合丹纳赫旗下行业领先技术生态系统中的AI、自动化和创新资源，助力研究人员将发现到突破的进程提速至多8倍

WASHINGTON

华盛顿

,

，

Oct. 7, 2026

2026年10月7日

/PRNewswire/ -- Danaher Corporation (NYSE:

/美通社/ -- 丹纳赫公司（纽约证券交易所：

DHR

DHR

) today announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently. Expected to operate at scale in early 2027, the lab will combine artificial intelligence, robotics and technologies from several Danaher operating companies in one connected workflow.

）今日宣布计划推出其首个由人工智能驱动的自主实验室，旨在帮助研究人员更快、更高效地开发定制抗体及其他分子工具。该实验室预计将于2027年初实现规模化运营，它将把人工智能、机器人技术以及丹纳赫旗下多家运营公司的技术整合到一个互联的工作流程中。

It is the first step in a broader Danaher initiative to create smart instruments, integrated workflows and autonomous labs that accelerate scientific research.

这是丹纳赫更广泛倡议中的第一步，旨在创建智能仪器、集成化工作流程和自动化实验室，以加速科学研究。

.

。

Danaher's first AI-powered autonomous lab is designed to deliver:

丹纳赫首个由人工智能驱动的自主实验室旨在提供：

Speed:

速度：

Up to 8x faster discovery of affinity reagents, helping researchers get from idea to breakthrough sooner

亲和力试剂的发现速度最高提升8倍，助力研究人员更快实现从构思到突破的跨越

Scale:

比例尺：

Unlocking up to a tenfold increase in annual reagent generation, from tens to hundreds of reagents per year as the lab scales

随着实验室规模的扩大，每年试剂生成量从数十种增加到数百种，实现高达十倍的增长

Quality:

质量：

Each design built in the lab would also be verified, tested and fed back to improve the next, without trading speed for scientific rigor

在实验室中构建的每个设计都将经过验证和测试，并将结果反馈用于改进下一个设计，同时在不牺牲科学严谨性的前提下保持速度。

Sustainability:

可持续性：

Over time, this approach is expected to complement traditional immunization-based methods used in the discovery of antibodies and other research tools

随着时间的推移，这种方法有望补充传统基于免疫的抗体发现及其他研究工具的方法。

'The autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver,' said Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher. 'By applying our science, technology and culture of continuous improvement, we can help turn promising ideas into validated systems faster.

“自主实验室体现了丹纳赫凭借独特优势所能实现的进步，”丹纳赫总裁兼首席执行官朱莉·索耶·蒙哥马利表示。“通过应用我们的科学、技术以及持续改进的文化，我们能够更快地将富有前景的创意转化为经验证的系统。”

It is an important step toward a future where AI, automation and intelligent systems dramatically accelerate the journey from discovery to impact.'.

这是迈向未来重要的一步，在未来，人工智能、自动化和智能系统将极大地加速从发现到产生影响的进程。

Based at Abcam, a Danaher company, the lab uses AI to help create new affinity reagents, including antibodies, then builds and tests each one, feeding every result back into the model to improve the next design. The lab brings together industry-leading technologies and expertise from several Danaher operating companies, including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices, in one connected workflow.

该实验室依托于丹纳赫旗下公司Abcam，利用人工智能辅助开发新型亲和试剂（包括抗体），随后对每一种试剂进行构建和测试，并将所有结果反馈至模型中，以优化下一轮设计。该实验室将丹纳赫多家运营公司的行业领先技术与专业知识整合到一个互联的工作流程中，这些公司包括贝克曼库尔特生命科学、Cytiva、Genedata、Integrated DNA Technologies以及Molecular Devices。

The device orchestration and robotic automation is the result of collaborative work with .

设备编排与机器人自动化是与……协作的成果。

Automata

自动机

*. This continuous design-make-test-learn loop can run in a fraction of the time it takes today, without trading speed for scientific rigor. This approach applies the same test-and-verify discipline of continuous improvement long used across Danaher operations to an AI-enabled laboratory environment.

*. 这种持续的“设计-制造-测试-学习”循环可以在比现在所需时间少得多的时间内运行，且不会以牺牲科学严谨性为代价来换取速度。这种方法将丹纳赫运营中长期采用的持续改进的测试与验证规范，应用于由人工智能赋能的实验室环境。

The lab is set to be an early proof point for how Danaher's smart instruments, AI-ready data, and expert agentic systems can accelerate scientific discovery and medical progress..

该实验室旨在成为早期验证案例，展示丹纳赫的智能仪器、就绪于人工智能的数据以及专家级智能体系统如何加速科学发现与医学进步。

'This lab represents a new model for scientific discovery, where AI, automation and human expertise work together in a continuous learning cycle,' said JC Gutierrez-Ramos, Senior Vice President and Chief Science Officer of Danaher. 'Speed is what supercharges that cycle. Every result sharpens the next design, so the faster each loop runs, the faster discovery compounds.

“该实验室代表了一种新的科学发现模式，其中人工智能、自动化与人类专业知识在持续的学习循环中协同工作，”丹纳赫公司高级副总裁兼首席科学官JC Gutierrez-Ramos表示。“速度是为这一循环注入强大动力的关键。每一项成果都会优化下一次设计，因此每个循环运行得越快，科学发现的积累效应就越显著。”

The lab is designed to deliver up to eight times faster progress from idea to validated reagent and up to a tenfold increase in reagent generation, while scientists continue to make the key decisions. That frees them to focus on the complex scientific challenges where human insight matters most.'.

该实验室旨在将从概念到验证试剂的进展速度提升至多八倍，并将试剂生成效率提高至多十倍，同时由科学家继续做出关键决策。这将使他们能够专注于人类洞察力最为重要的复杂科学挑战。

The lab is an example of a broader program across Danaher intended to create a fleet of smart instruments that are easier to integrate and control programmatically, produce AI-ready data, and include expert-level agentic systems designed to simplify operation, improve data quality and generate deeper insights.

该实验室是丹纳赫集团一项更广泛计划的典范，旨在打造一系列智能仪器，这些仪器更易于集成和程序化控制，能够生成适用于人工智能的数据，并包含专家级智能体系统，以简化操作、提高数据质量并产生更深入的洞察。

These intelligent devices can then be connected to create integrated workflows and autonomous labs that execute design-make-test-learn cycles. The approach also supports a shift toward more predictive and standardized research workflows, with models helping prioritize the most promising designs before they are made and robotics supporting more consistent experimentation..

这些智能设备可以相互连接，以创建集成化的工作流和自主实验室，从而执行“设计-制造-测试-学习”循环。该方法还支持向更具预测性和标准化的研究工作流转变，其中模型有助于在制造之前优先筛选最有前景的设计，而机器人技术则支持更一致的实验操作。

The platform reflects an important milestone in the Company's continued investment in connected science at a global scale: technologies designed to help researchers move from scientific question to validated answer with greater speed, consistency and confidence.

该平台标志着公司在全球范围内持续投资互联科学领域的一个重要里程碑：这些技术旨在帮助研究人员以更快的速度、更高的一致性和更强的信心，从科学问题迈向经过验证的答案。

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

前瞻性陈述及其他信息

Statements in this release that are not strictly historical, including statements regarding the Company's AI-powered autonomous lab, the anticipated timing, performance, capabilities and benefits of the platform, the development and deployment of smart instruments, integrated workflows and autonomous labs, and the expected impact of these technologies on biomedical research and scientific discovery, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are 'forward-looking' statements within the meaning of the federal securities laws.

本新闻稿中非严格属于历史事实的陈述，包括关于公司人工智能驱动的自主实验室、平台的预期时间表、性能、能力及益处、智能仪器、集成工作流和自主实验室的开发与部署，以及这些技术对生物医学研究和科学发现的预期影响的陈述，以及我们认为或预计将来会或可能发生的任何有关事件或发展的其他陈述，均属于联邦证券法意义上的“前瞻性”陈述。

There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S.

有许多重要因素可能导致实际结果、发展和业务决策与这些前瞻性陈述所暗示或指示的内容存在重大差异，您不应过度依赖任何此类前瞻性陈述。这些因素包括但不限于：美国实施的关税及相关措施的影响。

and other countries, the impact of our debt obligations (including debt we have incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and othe.

以及其他国家；我们的债务义务（包括为资助收购Masimo Corporation而产生的债务）对我们的运营和流动性的影响；全球经济、我们所服务的市场以及金融市场的恶化或不稳定；人工智能在我们业务和产品中的开发、部署和使用方面的不确定性；全球健康危机的影响；与国家法律或政策相关的不确定性，包括旨在保护或促进国内利益和/或应对外国竞争的法律或政策；我们成功识别并完成适当收购和战略投资的能力；我们整合所收购业务并实现预期增长、协同效应和其他

ABOUT DANAHER

关于丹纳赫

Danaher is a leading global life sciences and diagnostics innovator, committed to advancing the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—accelerating the moment scientific discovery becomes human impact.

丹纳赫是全球领先的生命科学与诊断创新者，致力于推动科技力量以改善人类健康。通过我们由行业领先企业组成的互联生态系统，我们与客户携手合作，解决他们面临的最复杂的科学和临床挑战——加速将科学发现转化为对人类的影响。

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

依托丹纳赫业务系统，我们先进的科学技术与经过验证的创新能力，有助于实现更快、更精准的诊断，并缩短发现、开发和交付变革性疗法所需的时间，降低其成本与风险。通过持续改进和卓越运营，我们全球约6万名员工致力于产生持久影响，改善世界各地的生活质量，同时构建一个更健康、更可持续的明天。

That's Innovation at the speed of life. Explore more at .

这就是与生活同步的创新速度。访问 以探索更多内容。

www.danaher.com

www.danaher.com

.

。

*Automata received an investment from DHR in Jan 2026

*Automata 于 2026 年 1 月获得 DHR 的投资

SOURCE Danaher Corporation

来源：丹纳赫公司

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示